Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Recombinant Human Meteorin
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Indaco Venture Partners
Deal Size : $25.0 million
Deal Type : Series A Financing
Details : The net proceeds will be used to advance new drug candidate, HB-086, a non-opioid compound with a unique mode of action, targeting the underlying cause in the peripheral nervous system against chronic neuropathic pain.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
December 11, 2023
Lead Product(s) : Recombinant Human Meteorin
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Indaco Venture Partners
Deal Size : $25.0 million
Deal Type : Series A Financing
Reset All
